222 citations
,
September 2016 in “JCI insight” This research overview highlights that although JAK inhibitors show promise as potential treatments for alopecia areata based on recent insights into the disease mechanism, their efficacy has not yet been thoroughly evaluated in a systematic manner.
196 citations
,
September 2016 in “JCI insight” This study explored the effectiveness of the oral JAK1/2 inhibitor ruxolitinib in treating patients with moderate-to-severe alopecia areata, building on prior success with JAK inhibitors in mice, but results are not reported in this abstract.
110 citations
,
August 2016 in “Drugs” Minoxidil is the only FDA-approved topical drug for treating male or female pattern hair loss, and other medications like finasteride and dutasteride can also increase hair growth.
2 citations
,
March 2015 in “Expert opinion on orphan drugs” This review discusses recent advances in the treatment of alopecia areata, highlighting new potential therapies like JAK inhibitors and PRP, and reports no new clinical results.
13 citations
,
March 2015 in “Plastic and reconstructive surgery. Global open” In this case report, eyelash transplantation with leg hair resulted in less frequent maintenance and no need for perming compared to using nape hair donor sources.
36 citations
,
January 2015 in “Dermatology” In this study, bimatoprost solution showed better results than corticosteroid in terms of rapidity, percentage of hair regrowth, and side effects for treating scalp alopecia areata.
17 citations
,
December 2013 in “Journal of Investigative Dermatology Symposium Proceedings” In this study, once-daily treatment with bimatoprost 0.03% solution significantly increased eyelash growth, thickness, and darkness in patients with chemotherapy-induced eyelash loss compared to placebo, and was well tolerated over one year.
37 citations
,
August 2013 in “Facial Plastic Surgery Clinics of North America” This review discusses facial hair transplantation techniques for natural-appearing results in restoring eyebrows, beards, goatees, sideburns, and repairing alopecic scarring, reporting no new clinical results.
43 citations
,
July 2013 in “Pharmacological reviews” This article reviews the pharmacology of bimatoprost and prostamide F2α, highlighting bimatoprost's therapeutic applications in glaucoma, hair growth, and potential fat reduction, without reporting new experimental results.
22 citations
,
April 2013 in “Dermatologic surgery” In this study, daily application of bimatoprost 0.03% ophthalmic solution for 9 months significantly improved eyebrow appearance in individuals with mild to moderate eyebrow hypotrichosis, without observed side effects.
29 citations
,
November 2012 in “Journal of The European Academy of Dermatology and Venereology” This review discusses the development of an algorithmic guideline for treating androgenetic alopecia in Asian patients, using the BASP classification to address limitations of previous guidelines, and reports no clinical results.
218 citations
,
April 2012 in “British Journal of Dermatology” This updated guideline from the British Association of Dermatologists discusses current recommendations for managing alopecia areata but reports no new clinical research findings.
81 citations
,
August 2011 in “Journal of The American Academy of Dermatology” In this study, latanoprost significantly increased hair density in young men with mild androgenetic alopecia after 24 weeks, suggesting it may stimulate hair follicle activity and treat hair loss.
29 citations
,
May 2010 in “Ophthalmology” Bimatoprost gel makes eyelashes grow longer, but may cause side effects and should be monitored by an eye doctor.
69 citations
,
April 2010 in “Clinical ophthalmology” This article reviews the use of bimatoprost for eyelash hypotrichosis and reports its effectiveness in promoting eyelash growth but highlights uncertain efficacy in cases of eyelash alopecia areata.
53 citations
,
March 2010 in “British Journal of Dermatology” This study found that androgenetic alopecia is the leading cause of hair loss in adolescents and may indicate endocrine disorders, emphasizing the need for accurate diagnosis.
35 citations
,
March 2010 in “British journal of dermatology/British journal of dermatology, Supplement” This study demonstrates that mouse eyelashes can effectively model human eyelash growth to analyze morphology, development, and the effects of growth-stimulatory agents like bimatoprost.
126 citations
,
January 2010 in “British Journal of Dermatology” This study found that the prevalence of androgenetic alopecia in Chinese men and women was lower than in Caucasians and similar to that in Koreans.
37 citations
,
January 2010 in “International Journal of Trichology” In this 1-year study of patients with alopecia areata universalis, researchers found that 0.03% topical bimatoprost led to an acceptable cosmetic response in 43.24% of participants.
50 citations
,
December 2009 in “Journal of The European Academy of Dermatology and Venereology” This study found that latanoprost may be effective for treating eyelash alopecia areata, achieving cosmetically acceptable regrowth in 45% of patients.
155 citations
,
March 2009 in “Seminars in Cutaneous Medicine and Surgery” This review covers various strategies to manage chemotherapy-induced alopecia, highlighting that agents like AS101 and minoxidil can reduce its severity but not prevent it, with no new clinical results reported.
21 citations
,
October 2008 in “Indian Journal of Plastic Surgery” This article discusses recent advancements in hair transplantation techniques that combine art and science for more natural results, but reports no new clinical findings.
179 citations
,
September 1998 in “BMJ” This article reviews the pathogenesis, genetic basis, and recent treatment breakthroughs for androgenetic alopecia but reports no new clinical findings.
216 citations
,
October 1997 in “American Journal of Ophthalmology” This study found that unilateral topical latanoprost use for glaucoma was associated with hypertrichosis and increased pigmentation of eyelashes in the treated eye compared to the untreated eye.
127 citations
,
July 1996 in “Journal of The American Academy of Dermatology” This study found that in women undergoing chemotherapy after breast surgery, topical minoxidil significantly shortened the duration of hair loss compared to a placebo without significant side effects.
33 citations
,
February 1990 in “Journal of the American Academy of Dermatology” Topical cyclosporine led to significant hair growth in some men with male pattern baldness.
101 citations
,
March 1987 in “Journal of The American Academy of Dermatology” Minoxidil solution helps hair regrowth in alopecia areata, with 5% being more effective.
104 citations
,
March 1987 in “Journal of The American Academy of Dermatology” Minoxidil helps hair growth in 63.6% of alopecia patients, with 27.3% having excellent results.
